$RGBPP News
Last published 1y ago
- 1y agoRGBPRGBPPRegen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025GlobeNewswireSAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC:RGBP) and (OTC:RGBPP) today announced the Company will be presenting an update on its application for Orphan Drug status to the U.S. Food and
- 1y agoRGBPRGBPPRegen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™GlobeNewswireTargeting Transformative Solutions for Aplastic Anemia and Beyond SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC:RGBP) today provided further insight into its planned Phase 1 clinical trial
- 4y agoONPHRGBPRGBPPOncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer VaccineACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC:ONPH) and Regen BioPharma, Inc. (OTC:RGBP) and (OTC:RGBPP): announced that they intend to work jointly to fast track the development of therapeutic uses relat
- 4y agoRGBPRGBPPRegen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine TechnologyPR NewswireSAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC:RGBP) and (OTC:RGBPP) is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. In the first phase of the developmen
- 4y agoRGBPRGBPPREGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICERPR NewswireSAN DIEGO, Dec. 30, 2021 /PRNewswire/ -- Regen BioPharma, Inc. (OTC:RGBP) and (OTC:RGBPP): First of all I would like to wish all our shareholders a happy holiday season. It has been a long year with many challenges and many successes. When
- 4y agoRGBPRGBPPRegen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized MedicinePR NewswireSAN DIEGO, Nov. 17, 2021 /PRNewswire/ -- Regen BioPharma, Inc. (OTC:RGBP) and (OTC:RGBPP) is currently completing a strategic analysis of its next 5 years of growth. As part of this analysis, diversifying beyond therapeutics into in-vitro diagnostics